Drug Profile
Research programme: HIV autoimmune therapy - Peptech/Retroscreen
Latest Information Update: 20 Feb 2008
Price :
$50
*
At a glance
- Originator Peptech UK
- Developer Peptech UK; Retroscreen Virology
- Class Antibodies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 20 Feb 2008 Discontinued - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
- 21 Aug 2001 This programme is still in active development
- 29 Jan 1999 New profile